Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
News|Slideshows|March 25, 2021
8 Neuropsychiatric Symptoms and Treatments of Huntington Disease
In approximately half of patients with Huntington disease, symptoms of depression, irritability/aggression, executive dysfunction, psychosis, cognitive decline, and dementia present long before progressive motor symptoms.
Advertisement
Advertisement
Related to this article
BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
New automated connectomics maps synapses across circuits, revealing how inhibitory neuron subtypes shape decision-making and may explain circuit dysfunction in psychiatric disorders.
Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Advertisement
Advertisement
Trending on Psychiatric Times
1
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
2
Assessing Interventions for Insomnia in Peri- and Postmenopausal Women
3
Presenting Our November 2026 Theme: Emergency Psychiatry
4
ALKS 7290 for Adjunctive Treatment for MDD Enters Phase 2 Study
5